Literature DB >> 12934113

Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets.

Miki Ohira1, Aiko Morohashi, Hiroyuki Inuzuka, Tomotane Shishikura, Takemasa Kawamoto, Hajime Kageyama, Yohko Nakamura, Eriko Isogai, Hajime Takayasu, Shigeru Sakiyama, Yutaka Suzuki, Sumio Sugano, Takeshi Goto, Shuji Sato, Akira Nakagawara.   

Abstract

Neuroblastoma (NBL), one of the most common childhood solid tumors, has a distinct nature in different prognostic subgroups: NBL in patients under 1 year of age usually regresses spontaneously, whereas that in patients over 1 year of age often grows aggressively and eventually kills the patient. To understand the molecular mechanism of biology and tumorigenesis of NBL, we decided to perform a comprehensive approach to unveil the gene expression profiles among the NBL subsets. We constructed the subset-specific oligo-capping cDNA libraries from the primary NBL tissues with favorable (F: stage 1, high expression of TrkA and a single copy of MYCN) and unfavorable (UF: stage 3 or 4, decreased expression of TrkA and MYCN amplification) characteristics and randomly cloned 4654 cDNAs. Among 4243 cDNAs sequenced successfully, 1799 (42.4%) were the genes with unknown function. Excluding the housekeeping genes, an expression profile of each subset was extremely different. To determine the genes expressed differentially between F and UF subsets, we performed semiquantitative reverse transcriptase (RT)-PCR for each of the 1842 independent genes using RNA obtained from 16 F and 16 UF NBLs as template. This revealed that 278 genes were highly expressed in the F subset as compared to the UF one, while, surprisingly, only 27 genes were expressed at higher levels in the UF rather than the F subset. These differentially expressed genes included 194 genes with unknown function. Many of the genes expressed at high levels in the F subset were related to catecholamine biosynthesis, small GTPases, synapse formation, synaptic vesicle transport, and transcription factors regulating differentiation of the neural crest-derived cells. On the other hand, the genes expressed at high levels in the UF subset included transcription factors and/or receptors that might regulate neuronal growth and differentiation. The chromosomal mapping of those genes showed some clusters. Thus, our mass-identification and characterization of the differentially expressed genes between the subsets may become a powerful tool for finding the important genes of NBL as well as developing new diagnostic and therapeutic strategies against aggressive NBL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12934113     DOI: 10.1038/sj.onc.1206853

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

1.  Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA.

Authors:  Matthias Fischer; Matthias Skowron; Frank Berthold
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

Review 2.  Gene profiling of high risk neuroblastoma.

Authors:  Sanjeev A Vasudevan; Jed G Nuchtern; Jason M Shohet
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

3.  Dependence receptor UNC5D mediates nerve growth factor depletion-induced neuroblastoma regression.

Authors:  Yuyan Zhu; Yuanyuan Li; Seiki Haraguchi; Meng Yu; Miki Ohira; Toshinori Ozaki; Atsuko Nakagawa; Toshikazu Ushijima; Eriko Isogai; Haruhiko Koseki; Yohko Nakamura; Cuize Kong; Patrick Mehlen; Hirofumi Arakawa; Akira Nakagawara
Journal:  J Clin Invest       Date:  2013-06-17       Impact factor: 14.808

4.  NDPKA is not just a metastasis suppressor - be aware of its metastasis-promoting role in neuroblastoma.

Authors:  Choon-Yee Tan; Christina L Chang
Journal:  Lab Invest       Date:  2017-10-09       Impact factor: 5.662

5.  The DMD locus harbours multiple long non-coding RNAs which orchestrate and control transcription of muscle dystrophin mRNA isoforms.

Authors:  Matteo Bovolenta; Daniela Erriquez; Emanuele Valli; Simona Brioschi; Chiara Scotton; Marcella Neri; Maria Sofia Falzarano; Samuele Gherardi; Marina Fabris; Paola Rimessi; Francesca Gualandi; Giovanni Perini; Alessandra Ferlini
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

6.  SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates.

Authors:  Bernd Schmidt; Volker Liebenberg; Dimo Dietrich; Thomas Schlegel; Christoph Kneip; Anke Seegebarth; Nadja Flemming; Stefanie Seemann; Jürgen Distler; Jörn Lewin; Reimo Tetzner; Sabine Weickmann; Ulrike Wille; Triantafillos Liloglou; Olaide Raji; Martin Walshaw; Michael Fleischhacker; Christian Witt; John K Field
Journal:  BMC Cancer       Date:  2010-11-03       Impact factor: 4.430

7.  Morphological and molecular assessment of apoptotic mechanisms in peripheral neuroblastic tumours.

Authors:  S Uccini; C Colarossi; S Scarpino; R Boldrini; P G Natali; M R Nicotra; F M Perla; O Mannarino; P Altavista; C Boglino; C A Cappelli; D Cozzi; A Donfrancesco; G Kokai; P D Losty; H P McDowell; C Dominici
Journal:  Br J Cancer       Date:  2006-06-06       Impact factor: 7.640

8.  Unravelling the RNA-Binding Properties of SAFB Proteins in Breast Cancer Cells.

Authors:  Elaine Hong; Andrew Best; Hannah Gautrey; Jas Chin; Anshuli Razdan; Tomaz Curk; David J Elliott; Alison J Tyson-Capper
Journal:  Biomed Res Int       Date:  2015-07-26       Impact factor: 3.411

9.  GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes.

Authors:  V Hoene; M Fischer; A Ivanova; T Wallach; F Berthold; C Dame
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

10.  NLRR1 Is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers.

Authors:  Atsushi Takatori; Md Shamim Hossain; Atsushi Ogura; Jesmin Akter; Yohko Nakamura; Akira Nakagawara
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.